REGN
$REGN
Regeneron Pharmaceuticals
Biotech company known for Eylea and Dupixent immunology drugs.
HealthcareSubscribers
1
Tracking this ticker
Latest Report
Analysis from Sep 26, 2026
REGN: Fundamentals, Pipeline, and Valuation
Regeneron (REGN) trades below several analyst targets while reporting strong margins, cash generation, and low leverage. This report examines valuation, catalysts, and risks heading into the long weekend.
Sep 27, 2026